TY - JOUR
T1 - Inflammatory mediators and the failing heart
T2 - Past, present, and the foreseeable future
AU - Mann, Douglas L.
PY - 2002/11/29
Y1 - 2002/11/29
N2 - Recent studies have identified the importance of proinflammatory mediators in the development and progression of heart failure. The growing appreciation of the pathophysiological consequences of sustained expression of proinflammatory mediators in preclinical and clinical heart failure models culminated in a series of multicenter clinical trials that used "targeted" approaches to neutralize tumor necrosis factor in patients with moderate to advanced heart failure. However, these targeted approaches have resulted in worsening heart failure, thereby raising a number of important questions about what role, if any, proinflammatory cytokines play in the pathogenesis of heart failure. This review will summarize the tremendous growth of knowledge that has taken place in this field, with a focus on what we have learned from the negative clinical trials, as well as the potential direction of future research in this area.
AB - Recent studies have identified the importance of proinflammatory mediators in the development and progression of heart failure. The growing appreciation of the pathophysiological consequences of sustained expression of proinflammatory mediators in preclinical and clinical heart failure models culminated in a series of multicenter clinical trials that used "targeted" approaches to neutralize tumor necrosis factor in patients with moderate to advanced heart failure. However, these targeted approaches have resulted in worsening heart failure, thereby raising a number of important questions about what role, if any, proinflammatory cytokines play in the pathogenesis of heart failure. This review will summarize the tremendous growth of knowledge that has taken place in this field, with a focus on what we have learned from the negative clinical trials, as well as the potential direction of future research in this area.
KW - Clinical trial
KW - Etanercept
KW - Inflammatory mediators
KW - Infliximab
KW - Tumor necrosis factor
UR - http://www.scopus.com/inward/record.url?scp=0037195727&partnerID=8YFLogxK
U2 - 10.1161/01.RES.0000043825.01705.1B
DO - 10.1161/01.RES.0000043825.01705.1B
M3 - Review article
C2 - 12456484
AN - SCOPUS:0037195727
SN - 0009-7330
VL - 91
SP - 988
EP - 998
JO - Circulation research
JF - Circulation research
IS - 11
ER -